Dacomitinib

규격

1110813-31-4CAS 번호

(E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamideIUPAC 명칭

C24H25ClFN5O2화학식

469.9 g/mol분자량

Dacomitinib; 1110813-31-4; PF-00299804; Dacomitinib anhydrous; Vizimpro; dacomitinibum; PF-299804; 2XJX250C20; pf00299804; PF 00299804-03; PF-00299804-03; (2e)-N-{4-[(3-Chloro-4-Fluorophenyl)amino]-7-Methoxyquinazolin-6-Yl}-4-(Piperidin-1-Yl)but-2-Enamide; CHEBI:132268; DTXSID50149493; (2E)-N-(4-((3-CHLORO-4-FLUOROPHENYL)AMINO)-7-METHOXYQUINAZOLIN-6-YL)-4-PIPERIDIN-1-YLBUT-2-ENAMIDE; 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-, (2E)-; (2E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide; (E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-piperidin-1-ylbut-2-enamide; (E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide; 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-, hydrate (1:1), (2E)-; RefChem:585148; DTXCID8071984; L01XE47; EGFR Inhibitor PF-00299804; (2E)-N-(4-(3-Chloro-4-fluorophenyl)amino)7-methoxyquinazolin-6-yl)4-(piperidin-1-yl)but-2-enamide monohydrate; 1042385-75-0; 5092U85G58; Dacomitinib (PF299804, PF299); PF299804; Dacomitinib (PF299804); (E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enaMide; (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide; MFCD19443734; Dacomitinib [USAN:INN]; Dacomitinib (INN); (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide; DACOMITINIB [INN]; C24H25ClFN5O2; (2E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide; PF 00299804; UNII-2XJX250C20; Dacomitinib (PF-00299804); (E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide; 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-, (2E)-; (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide; Dacomitinib; PF 00299804; PF 299; PF 299804; Dacomitinib (Standard); SCHEMBL33147; DACOMITINIB [WHO-DD]; MLS006011275; GTPL7422; orb1305418; CHEMBL2110732; SCHEMBL29354322; SCHEMBL29377735; CHEBI:91466; EX-A030; BDBM112499; GLXC-90191; HMS5081D15; EBC-24037; HY-13272R; NSC765888; NSC800084; s2727; AKOS025401818; CCG-264987; CS-0500; DB11963; FD64992; NSC-765888; NSC-800084; SDCCGSBI-0646934.P001; US8623883, No. 2; NCGC00263185-06; NCGC00263185-09; NCGC00263185-10; AC-25915; AS-57686; BP-43638; DA-56723; HY-13272; SMR004703025; D5450; NS00072953; SW219155-1; T2483; D09883; Dacomitinib (PF299804, PF-00299804); PF-299804 (Dacomitinib PF-00299804); EN300-7406881; PF-299804 (Dacomitinib,PF-00299804)?; D004098; BRD-K57169635-001-04-5; Q17130597; (E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide; (E)-N-[4-(3-chloro-4-fluoro-anilino)-7-methoxy-quinazolin-6-yl]-4-(1-piperidyl)but-2-enamide; Dacomitinib Hydrate동의어